Nebenwirkungen · Rebif
Rebif 22 micrograms solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 53
HOS-086830 · Präparat HOS-083347
The adverse reactions presented have been identified from clinical studies as well as from post- marketing reports (an asterisk [*] indicates adverse reactions identified during post-marketing surveillance). The following definitions apply to the frequency terminology used hereafter: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), frequency not known (cannot be estimated from the available data).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-02T14:48:00Z · SHA-256 c6ab8814b49946dc4207aa21171665843c7aa81527cc4b3faf99df87529e0907 · Passage 15b3520f925cbf9bd215d6cdff16b90925efcc59cd72e5dcb895bee0cf9ce0f3 · Zeichen 996–1478 im Abschnitt